1. Medtech Insight
  2. >>Device Area
  3. >>Neurology

QUOTED. 9 October 2020. Keith Xavier.

Medtronic said its next-generation InterStim Micro system for overactive bladder has been implanted in the first patient in the ELITE study, which seeks to evaluate the safety and performance of the US FDA-approved device. See what Keith Xavier, a founding partner at Urology Partners of North Texas who implanted the first patient, said about it here.

Quoted Column

“Through the Elite study, our goal is to further validate existing data that sacral neurostimulation is a safe, long-term solution for patients who are limited professionally, personally and socially by their condition.” – Keith Xavier, partner, Urology Partners of North Texas

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurology

THENA Capital ‘Makes History’ As UK’s First All-Female Early-Stage Medtech Fund

 
• By Natasha Barrow

Only 16% of venture capital general partners in Europe are women, and only 9% of those have actual investment power. Thena Capital is aiming to "redefine the image of a venture capitalist."

Wired Health: ‘Early Diagnosis Often Benefits Science But Not The Patient’

 
• By Natasha Barrow

Early diagnosis can be “detrimental” to patients, Suzanne O'Sullivan, neurologist and author of “The Age of Diagnosis,” argued at the Wired Health conference on 18 March. "You save one life from screening 2,000 women for breast cancer, but you also treat 10 women unnecessarily," she said.

Barcelona’s S2 Xpeed Accelerates Hardware-Based Medtech Start-Ups From Prototype To Market

 
• By Marion Webb

Barcelona-based accelerator S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity. This month, the accelerator will add a fourth cohort of 10 more start-ups, five of which are in the medtech space.

Class I Recall On Medtronic Embolization Device After 4 Deaths

 
• By Elizabeth Orr

The company is recalling Pipeline Vantage 021 and 027 models because they pose a higher than normal risk of failing to properly attach to blood vessel walls, which can cause thrombosis, stroke or death. The recall for 027 is a product removal and for 021 is an update to the instructions for use.

More from Device Area

MedStar Teams Up With Reimagine Care To Extend Cancer Care Into Patients’ Home

 
• By Marion Webb

Reimagine Care teamed up with MedStar Health to support cancer patients at home via an AI assistant and clinical support. Reimagine Care’s data suggests its platform can save cancer centers up to $1m annually per full-time oncologist panel and reduce ED visits by 30%.

Dexcom Promotes CGM As First-Line Tool In Type 2 Diabetes

 
• By Shubham Singh

Only 14% of people with type 2 diabetes use continuous glucose monitors, although 93% of users report a positive impact on their health. Dexcom is ramping up efforts to close this adoption gap.

Gleamer Charts Multi-Modality Future With FDA Nod And MRI Acquisitions

 
• By Shubham Singh

ChestView, Gleamer’s newly FDA-cleared solution, is designed for chest X-ray interpretation and is the latest addition to its Gleamer Copilot suite. ChestView, which operates as a computer-aided detection system that can simultaneously detect multiple pathologies on images to support radiologists, is being rolled out in the US.